Clinical Trials Directory

Trials / Completed

CompletedNCT00992095

Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted Conditions

A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalency Study of Buprenorphine HCl (Sublingual) 8 mg Tablets With a Naltrexone Block Under Fasting Conditions

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
48 (actual)
Sponsor
Roxane Laboratories · Industry
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The objective of this study was to prove the bioequivalence of Buprenorphine HCl 8 mg tablet under fasted conditions.

Conditions

Interventions

TypeNameDescription
DRUGbuprenorphine hydrochloridesingle dose 8 mg sublingual tablet

Timeline

Start date
2006-08-01
Primary completion
2006-09-01
Completion
2006-09-01
First posted
2009-10-09
Last updated
2018-01-23

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00992095. Inclusion in this directory is not an endorsement.

Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted Conditions (NCT00992095) · Clinical Trials Directory